FDA approves first new drug for ALS in decades

May 8, 2017

(HealthDay)—The first new drug to treat amyotrophic lateral sclerosis (ALS) in more than 20 years has been approved by the U.S. Food and Drug Administration.

Radicava (edaravone) is taken intravenously daily for 14 days, followed by 14 days without the drug. Subsequent treatment cycles consist of treatment for 10 out of 14 days, followed by 14 days without the drug.

"After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States," Dr. Eric Bastings, deputy director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option," Bastings added.

The very first ALS drug, riluzole, was approved by the FDA in 1995.

ALS, also known as Lou Gehrig's disease, is a progressive, always fatal neurological disease that destroys the nerve cells that control voluntary muscles, including those used for chewing, walking, breathing and talking. Most patients die from respiratory failure within three to five years after symptoms begin.

About 12,000 to 15,000 Americans have ALS, according to the U.S. Centers for Disease Control and Prevention.

The FDA's approval of Radicava was based on a six-month clinical trial in Japan that included 137 patients who received either the drug or an inactive placebo, the agency said Friday. After 24 weeks, patients taking the drug had less decline in physical functioning than those taking the placebo.

The most common side effects among patients taking the drug were bruising and walking problems, the findings showed.

"Radicava is also associated with serious risks that require immediate medical care, such as hives, swelling or shortness of breath, and [life-threatening] allergic reactions to sodium bisulfite, an ingredient in the drug," the agency said in the news release.

One ALS expert said the approval gives patients a desperately needed option.

"The effect is modest but significant," Dr. Neil Shneider, director of the Eleanor and Lou Gehrig ALS Center at Columbia University Medical Center in New York City, told The New York Times. "I'm very happy, frankly, that there is a second drug approved for ALS."

But Shneider stopped short of saying he would actually recommend it to his ALS patients, because the intravenous drug is difficult and time-consuming to administer.

"If it were a pill and easily administered, I'd be less reluctant to use it," he told the newspaper.

Shneider added that the will not make feel better or stronger; it can only slow the decline of the devastating disease.

Explore further: 1st drug for tardive dyskinesia approved

More information: U.S. Food and Drug Administration, news release, May 5, 2017; The New York Times

The U.S. National Institute of Neurological Disorders and Stroke has more on ALS.

Related Stories

1st drug for tardive dyskinesia approved

April 12, 2017
(HealthDay)—Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.

Brineura approved for rare genetic illness affecting kids

April 28, 2017
(HealthDay)—Brineura (cerliponase alfa) has been approved by the U.S. Food and Drug Administration to treat a specific form of Batten Disease, a rare set of genetic disorders that typically begin in childhood between ages ...

FDA approves injectable psoriasis drug for tough cases

February 16, 2017
(HealthDay)—A new drug to treat tough cases of the skin condition psoriasis has won approval from the U.S. Food and Drug Administration.

FDA approves new drug for schizophrenia, major depression

July 13, 2015
(HealthDay)—A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration.

FDA panel votes against approval of eteplirsen for DMD

April 27, 2016
(HealthDay)—The drug eteplirsen should not be approved for treatment of Duchenne muscular dystrophy, a U.S. Food and Drug Administration advisory panel said Monday.

Battery-operated skin patch offers new option for migraine sufferers

March 26, 2013
(HealthDay)—The first skin patch approved to treat migraines offers patients an alternative to pills, nasal sprays and injections, the U.S. Food and Drug Administration says.

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.